Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure

Š. Vacková, S. Kikerlová, V. Melenovsky, F. Kolář, JD. Imig, E. Kompanowska-Jezierska, J. Sadowski, L. Červenka,

. 2019 ; 44 (4) : 792-809. [pub] 20190820

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006016

OBJECTIVE: We evaluated the hypothesis that the development of renal dysfunction and congestive heart failure (CHF) caused by volume overload in rats with angiotensin II (ANG II)-dependent hypertension is associated with altered renal vascular responsiveness to ANG II and to epoxyeicosatrienoic acids (EETs). METHODS: Ren-2 transgenic rats (TGRs) were used as a model of ANG II-dependent hypertension. CHF was induced by volume overload achieved by the creation of the aorto-caval fistula (ACF). Renal blood flow (RBF) responses were determined to renal arterial administration of ANG II, native 11,12-EET, an analog of 14,15-EETs (EET-A), norepinephrine (NE), acetylcholine (Ach) and bradykinin (Bk) in healthy (i.e., sham-operated) TGR and ACF TGR (5 weeks after ACF creation). RESULTS: Selective intrarenal administration of neither vasoactive drug altered mean arterial pressure in any group. Administration of ANG II caused greater decreases in RBF in ACF TGR than in sham-operated TGR, whereas after administration of NE the respective decreases were comparable in the 2 groups. Administration of Ach and Bk elicited significantly higher RBF increases in ACF TGR as compared with sham-operated TGR. In contrast, administration of 11,12-EET and EET-A caused significantly smaller RBF increases in ACF TGR than in sham-operated TGR. CONCLUSION: The findings show that 5 weeks after creation of ACF, the TGR exhibit exaggerated renal vasoconstrictor responses to ANG II and reduced renal vasodilatory responses to EETs, suggesting that both these alterations might play an important role in the development of renal dysfunction in this model of CHF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006016
003      
CZ-PrNML
005      
20220530151634.0
007      
ta
008      
200511s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000501688 $2 doi
035    __
$a (PubMed)31430751
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Vacková, Šárka $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia.
245    10
$a Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure / $c Š. Vacková, S. Kikerlová, V. Melenovsky, F. Kolář, JD. Imig, E. Kompanowska-Jezierska, J. Sadowski, L. Červenka,
520    9_
$a OBJECTIVE: We evaluated the hypothesis that the development of renal dysfunction and congestive heart failure (CHF) caused by volume overload in rats with angiotensin II (ANG II)-dependent hypertension is associated with altered renal vascular responsiveness to ANG II and to epoxyeicosatrienoic acids (EETs). METHODS: Ren-2 transgenic rats (TGRs) were used as a model of ANG II-dependent hypertension. CHF was induced by volume overload achieved by the creation of the aorto-caval fistula (ACF). Renal blood flow (RBF) responses were determined to renal arterial administration of ANG II, native 11,12-EET, an analog of 14,15-EETs (EET-A), norepinephrine (NE), acetylcholine (Ach) and bradykinin (Bk) in healthy (i.e., sham-operated) TGR and ACF TGR (5 weeks after ACF creation). RESULTS: Selective intrarenal administration of neither vasoactive drug altered mean arterial pressure in any group. Administration of ANG II caused greater decreases in RBF in ACF TGR than in sham-operated TGR, whereas after administration of NE the respective decreases were comparable in the 2 groups. Administration of Ach and Bk elicited significantly higher RBF increases in ACF TGR as compared with sham-operated TGR. In contrast, administration of 11,12-EET and EET-A caused significantly smaller RBF increases in ACF TGR than in sham-operated TGR. CONCLUSION: The findings show that 5 weeks after creation of ACF, the TGR exhibit exaggerated renal vasoconstrictor responses to ANG II and reduced renal vasodilatory responses to EETs, suggesting that both these alterations might play an important role in the development of renal dysfunction in this model of CHF.
650    _2
$a angiotensin II $x škodlivé účinky $7 D000804
650    _2
$a zvířata $7 D000818
650    _2
$a arterioarteriální píštěl $x patofyziologie $7 D001159
650    _2
$a srdeční selhání $x komplikace $x patofyziologie $7 D006333
650    _2
$a hypertenze $x chemicky indukované $x komplikace $7 D006973
650    _2
$a arteria pulmonalis $x abnormality $x patofyziologie $7 D011651
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renální oběh $x účinky léků $7 D012079
650    _2
$a vazokonstrikce $x účinky léků $7 D014661
650    _2
$a vazokonstriktory $x farmakologie $7 D014662
650    _2
$a vazodilatace $x účinky léků $7 D014664
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kikerlová, Soňa, $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia. $d 1978- $7 xx0256886
700    1_
$a Melenovsky, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czechia.
700    1_
$a Kolář, František $u Department of Developmental Cardiology, Institute of Physiology of the Czech Academy of Sciences, Prague, Czechia.
700    1_
$a Imig, John D $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
700    1_
$a Kompanowska-Jezierska, Elżbieta, $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland. $d 1959- $7 xx0273376
700    1_
$a Sadowski, Janusz $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland.
700    1_
$a Červenka, Luděk $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czechia, luce@medicon.cz.
773    0_
$w MED00003064 $t Kidney & blood pressure research $x 1423-0143 $g Roč. 44, č. 4 (2019), s. 792-809
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31430751 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20220530151632 $b ABA008
999    __
$a ok $b bmc $g 1524874 $s 1096072
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 44 $c 4 $d 792-809 $e 20190820 $i 1423-0143 $m Kidney & blood pressure research $n Kidney Blood Press Res $x MED00003064
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace